
  
    
      
        Background_NNP
        Human_JJ breast_NN tumorigenesis_NNS is_VBZ a_DT multistage_NN process_NN
        encompassing_VBG complex_JJ cellular_JJ transformation_NN from_IN normalcy_NN
        to_TO malignancy_NN [_NN 1_CD ]_NN ._. It_PRP has_VBZ been_VBN proposed_VBN that_IN multiple_JJ ,_,
        different_JJ cellular_JJ events_NNS dictate_VBP the_DT biochemical_JJ changes_NNS
        that_WDT allow_VBP normal_JJ cells_NNS to_TO become_VB highly_RB malignant_JJ ._. These_DT
        key_JJ events_NNS require_VBP alterations_NNS in_IN the_DT expression_NN of_IN many_JJ
        genes_NNS ,_, translation_NN of_IN RNA_NNP transcripts_NNS ,_, and_CC cellular_JJ
        activation_NN by_IN growth_NN factors_NNS ,_, hormones_NNS and_CC proteins_NNS in_IN the_DT
        evolving_VBG tumor_NN cell_NN population_NN [_NN 1_CD 2_CD 3_CD 4_CD 5_CD ]_NN ._.
        Steroid_NNP hormones_NNS play_VBP a_DT vital_JJ role_NN in_IN the_DT growth_NN of_IN
        normal_JJ mammary_JJ gland_NN tissue_NN ,_, as_RB well_RB as_RB ,_, the_DT development_NN
        and_CC progression_NN of_IN breast_NN tumors_NNS ._. Human_JJ estrogen_NN receptor_NN
        alpha_NN (_( hERα_NN )_) is_VBZ detected_VBN in_IN 50_CD -_: 85_CD %_NN of_IN all_DT breast_NN tumors_NNS [_NN 6_CD
        ]_NN ,_, and_CC is_VBZ utilized_JJ as_IN a_DT prognostic_JJ marker_NN to_TO identify_VB
        patients_NNS who_WP may_MD have_VB a_DT favorable_JJ response_NN to_TO hormonal_NN or_CC
        endocrine_NN manipulations_NNS ._. Thus_RB ,_, hERα_NN provides_VBZ a_DT useful_JJ
        prognostic_JJ index_NN in_IN patients_NNS with_IN metastatic_JJ disease_NN and_CC is_VBZ
        associated_VBN with_IN disease-free_JJ survival_NN [_NN 7_CD 8_CD 9_CD 10_CD ]_NN ._.
        However_RB ,_, 35_CD %_NN of_IN all_DT patients_NNS with_IN hERα_NN positive_JJ (_( ER_NNP +_NN )_)
        tumors_NNS do_VBP not_RB respond_VB to_TO hormonal_NN interventions_NNS suggesting_VBG
        cellular_JJ and_CC molecular_JJ alterations_NNS [_NN 6_CD 11_CD 12_CD ]_NN ._.
        This_DT lack_NN of_IN response_NN may_MD be_VB attributed_VBN ,_, at_IN least_JJS in_IN
        part_NN ,_, to_TO the_DT presence_NN of_IN nonfunctional_NN hERα_NN as_IN determined_VBN
        by_IN the_DT inability_NN of_IN hERα_NN to_TO bind_NN hormone_NN ,_, to_TO recognize_VB and_CC
        bind_NN to_TO specific_JJ DNA-responsive_NNP elements_NNS and_CC /_NN or_CC its_PRP$
        inability_NN to_TO recruit_VB other_JJ transcriptional_NN activation_NN
        factors_NNS [_NN 6_CD 11_CD 12_CD ]_NN ._. It_PRP may_MD also_RB be_VB attributed_VBN to_TO tumor_NN
        heterogeneity_NN in_IN which_WDT some_DT tumor_NN cells_NNS may_MD continue_VB to_TO
        express_VB functional_JJ hERα_NN while_IN other_JJ cells_NNS may_MD express_VB
        either_CC dysfunctional_NN hERα_NN or_CC do_VBP not_RB express_VB hERα_NN at_IN all_DT ._.
        This_DT may_MD permit_VB the_DT tumor_NN to_TO become_VB autonomous_JJ with_IN respect_NN
        to_TO hormone_NN sensitivity_NN ,_, allowing_VBG tumor_NN progression_NN ._.
        Currently_RB ,_, human_JJ breast_NN tumor_NN hERα_NN content_NN is_VBZ determined_VBN by_IN
        ligand-binding_JJ assays_NNS or_CC immunohistochemistry_NN ._. While_IN these_DT
        techniques_NNS measure_NN either_CC hERα_NN content_NN or_CC its_PRP$ cellular_JJ
        distribution_NN ,_, they_PRP do_VBP not_RB provide_VB the_DT means_NNS for_IN assessing_VBG
        hERα_NN functionality_NN ._.
        In_IN our_PRP$ search_NN for_IN new_JJ tumor_NN markers_NNS ,_, we_PRP identified_VBD and_CC
        characterized_VBD a_DT novel_NN 55_CD kDa_NN nuclear_JJ protein_NN ,_, termed_VBD nmt_NN 55_CD
        [_NN 13_CD ]_NN ._. The_DT amino_JJ acid_NN sequence_NN of_IN nmt_NN 55_CD was_VBD highly_RB
        homologous_RB ,_, but_CC not_RB identical_JJ ,_, to_TO that_DT reported_VBD for_IN the_DT
        nuclear_JJ protein_NN p_NN 54_CD nrbidentified_JJ in_IN HeLa_NNP cells_NNS [_NN 14_CD ]_NN ._. A_DT
        more_RBR recent_JJ report_NN by_IN Peters_NNP et_CC al_NN ._. [_NN 15_CD ]_NN noted_VBD
        differences_NNS in_IN the_DT sequence_NN of_IN the_DT reported_VBN HeLa_NNP cell_NN p_NN 54_CD
        nrb_NN [_NN 14_CD ]_NN and_CC placental_NN p_NN 54_CD nrb_NN ._. When_WRB we_PRP compared_VBD the_DT
        sequences_NNS of_IN nmt_NN 55_CD and_CC placental_NN p_NN 54_CD nrb_NN (_( U_NNP ._. Muller_NNP ,_,
        Personal_NNP Communication_NNP )_) ,_, we_PRP determined_VBD that_IN the_DT sequences_NNS
        were_VBD identical_JJ ._. The_DT differences_NNS in_IN the_DT sequence_NN for_IN nmt_NN 55_CD ,_,
        placental_NN p_NN 54_CD nrband_NN HeLa_NNP p_NN 54_CD nrbare_NN most_RBS likely_JJ due_NN to_TO
        HeLa_NNP p_NN 54_CD nrbsequencing_VBG error_NN ._. Chromosomal_NNP location_NN and_CC
        sequence_NN identity_NN data_NNS confirm_VBP that_DT p_NN 54_CD nrbhas_NNS the_DT same_JJ
        sequence_NN as_IN nmt_NN 55_CD and_CC are_VBP the_DT same_JJ gene_NN ._. We_PRP refer_VBP to_TO this_DT
        protein_NN as_IN nmt_NN 55_CD /_NN p_NN 54_CD nrb_NN ._.
        Our_PRP$ studies_NNS on_IN nmt_NN 55_CD and_CC those_DT of_IN p_NN 54_CD nrbhave_NN
        characterized_VBD this_DT protein_NN as_IN an_DT RNA_NNP binding_JJ protein_NN with_IN
        the_DT ability_NN to_TO associate_JJ with_IN Topoisomerase_NNP I_PRP and_CC the_DT
        polypyrimidine_NN tract-binding_JJ protein_NN associated_VBN splicing_VBG
        factor_NN (_( PSF_NNP )_) [_NN 16_CD 17_CD 18_CD 19_CD 20_CD ]_NN ._. Further_RB ,_, we_PRP observed_VBD the_DT
        association_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbwith_NN several_JJ splicing_VBG factors_NNS
        known_VBN to_TO be_VB essential_JJ for_IN spliceosome_NN formation_NN suggesting_VBG
        a_DT role_NN for_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbin_NN pre-m_JJ RNA_NNP splicing_VBG (_( unpublished_JJ
        results_NNS )_) ._.
        Our_PRP$ previous_JJ studies_NNS investigated_VBD the_DT protein_NN expression_NN
        of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbin_NN human_JJ breast_NN tumors_NNS using_VBG a_DT monoclonal_NN
        antibody_NN with_IN an_DT epitope_NN localized_VBN to_TO the_DT carboxyl_NN terminal_NN
        domain_NN of_IN this_DT protein_NN ._. These_DT studies_NNS demonstrated_VBD a_DT
        statistically_RB significant_JJ association_NN between_IN nmt_NN 55_CD /_NN p_NN 54_CD
        nrbprotein_NN expression_NN ,_, tumor_NN hormonal_NN phenotype_NN and_CC mean_VB
        tumor_NN size_NN [_NN 13_CD ]_NN ._. Specifically_RB ,_, in_IN tumors_NNS large_JJ in_IN size_NN
        or_CC those_DT tumors_NNS which_WDT were_VBD determined_VBN to_TO be_VB ER-_NNP ,_, the_DT
        expression_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN was_VBD absent_JJ ,_, or_CC greatly_RB
        reduced_VBN [_NN 13_CD ]_NN ._. These_DT results_NNS suggested_VBD that_DT loss_NN of_IN
        nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN expression_NN may_MD be_VB related_VBN to_TO hormone_NN
        insensitivity_NN ,_, tumor_NN differentiation_NN state_NN ,_, unregulated_JJ
        tumor_NN growth_NN and_CC metastases_NNS ._.
        The_DT absence_NN or_CC reduced_VBN expression_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbmay_NN be_VB
        attributed_VBN to_TO the_DT regulation_NN of_IN mRNA_NN expression_NN ,_, protein_NN
        processing_NN of_IN a_DT specific_JJ functional_JJ domain_NN or_CC the_DT presence_NN
        of_IN a_DT heterogeneous_JJ population_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbisoforms_NNS
        which_WDT may_MD not_RB be_VB immunodetected_JJ by_IN monoclonal_NN antibody_NN
        NMT-_NNP 1_CD ._. In_IN this_DT study_NN ,_, we_PRP compared_VBD mRNA_NN levels_NNS in_IN ER_NNP +_NN and_CC
        ER-_NNP human_JJ breast_NN tumors_NNS using_VBG Northern_NNP blot_NN analysis_NN and_CC
        ribonuclease_NN protection_NN assay_NN to_TO assess_VB if_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbis_NNS
        regulated_VBN at_IN the_DT transcription_NN level_NN ._. We_PRP further_RBR developed_VBN ,_,
        nmt_NN 55_CD /_NN p_NN 54_CD nrbspecific_JJ ,_, site-directed_JJ polyclonal_NN antibodies_NNS
        to_TO the_DT amino_JJ terminal_NN region_NN and_CC to_TO a_DT mid-region_JJ to_TO assess_VB
        the_DT potential_JJ presence_NN of_IN multiple_JJ nmt_NN 55_CD /_NN p_NN 54_CD nrbisoforms_NNS or_CC
        processed_VBN nmt_NN 55_CD /_NN p_NN 54_CD nrbin_NN human_JJ breast_NN tumors_NNS ._.
      
      
        Methods_NNP
        
          Isotopes_NNP ,_, reagents_NNS and_CC chemicals_NNS
          [_NN 2_CD ,_, 4_CD ,_, 6_CD ,_, 7_CD -_: 3_CD H_NNP ]_NN Oestradiol_NNP (_( [_NN 3_CD H_NNP ]_NN E_NNP 
          2_LS )_) (_( 102_CD Ci_NNP /_NN mmol_NN )_) was_VBD obtained_VBN from_IN
          Amersham_NNP (_( Arlington_NNP Heights_NNP ,_, IL_NNP )_) ._. α-_NN 32_CD P_NN CTP_NNP (_( 800_CD
          Ci_NNP /_NN mmol_NN )_) and_CC γ-_NN 32_CD P_NN ATP_NNP (_( 3000_CD Ci_NNP /_NN mmol_NN )_) were_VBD obtained_VBN from_IN
          New_NNP England_NNP Nuclear_NNP (_( Boston_NNP ,_, Ma_NNP )_) ._. Unlabeled_NNP
          diethylstilbestrol_NN (_( DES_NNP )_) was_VBD obtained_VBN from_IN Steraloids_NNP
          (_( Wilton_NNP ,_, NH_NNP )_) ._. Monoclonal_NNP antibodies_NNS NMT-_NNP 1_CD and_CC EVG_NNP F_NNP 9_CD were_VBD
          developed_VBN to_TO unique_JJ peptides_NNS encompassing_VBG amino_JJ acids_NNS
          140_CD -_: 154_CD and_CC 140_CD -_: 154_CD -_: 247_CD -_: 263_CD of_IN hERα_NN ,_, respectively_RB [_NN 21_CD 22_CD
          23_CD 24_CD ]_NN ._. Monoclonal_NNP antibody_NN 4_CD ._. 14_CD was_VBD raised_VBN against_IN a_DT
          peptide_NN representing_VBG amino_JJ acid_NN sequence_NN 533_CD -_: 547_CD of_IN human_JJ
          progesterone_NN receptor_NN (_( hPR_NN )_) [_NN 25_CD ]_NN ._. All_DT other_JJ chemicals_NNS
          were_VBD reagent_NN grade_NN and_CC were_VBD obtained_VBN from_IN commercial_JJ
          sources_NNS ._.
        
        
          Human_JJ tissue_NN and_CC cell_NN lines_NNS
          Human_JJ breast_NN cancer_NN tissue_NN was_VBD obtained_VBN from_IN patients_NNS
          undergoing_VBG surgery_NN for_IN the_DT treatment_NN of_IN breast_NN cancer_NN ,_, as_IN
          described_VBN previously_RB [_NN 26_CD ]_NN ._. The_DT MCF-_NNP 7_CD human_JJ
          adenocarcinoma_NN cell_NN line_NN was_VBD obtained_VBN from_IN the_DT American_NNP
          Type_NNP Tissue_NNP Culture_NNP Collection_NNP (_( Manassas_NNP ,_, VA_NNP )_) ._.
        
        
          Buffers_NNP and_CC solutions_NNS
          TEGT_NNP Buffer_NNP consisted_VBD of_IN 50_CD mM_NN Tris-_NNP HCl_NNP ,_, 10_CD %_NN [_NN vol_NN /_NN vol_NN ]_NN
          glycerol_NN ,_, 1_CD mM_NN EDTA_NNP ,_, 0_CD ._. 02_CD %_NN [_NN wt_NN /_NN vol_NN ]_NN sodium_NN azide_NN and_CC 10_CD
          mM_NN monothioglycerol_NN ,_, pH_NN 7_CD ._. 4_CD ,_, at_IN 4_CD °_NN C_NNP ._. TGET_NNP /_NN MO_NNP buffer_NN was_VBD
          TGET_NNP buffer_NN containing_VBG 10_CD mM_NN sodium_NN molybdate_NN ._. TBST_NNP
          buffer_NN consisted_VBD of_IN 50_CD mM_NN Tris-_NNP HCl_NNP ,_, 0_CD ._. 15_CD M_NNP NaCl_NNP ,_, and_CC 0_CD ._. 5_CD %_NN
          Tween_NNP 20_CD ,_, pH_NN 8_CD ._. 0_CD ._.
        
        
          Cytosol_NNP and_CC nuclear_JJ extract_NN preparation_NN
          Cytosols_NNP were_VBD prepared_VBN as_IN described_VBN [_NN 22_CD 27_CD 28_CD 29_CD ]_NN ._.
          Briefly_NNP ,_, tissue_NN was_VBD homogenized_JJ (_( 0_CD ._. 5_LS g_SYM /_NN 3_CD ml_NN )_) in_IN TEGT_NNP /_NN MO_NNP
          buffer_NN ._. The_DT homogenate_NN was_VBD centrifuged_JJ at_IN 100_CD ,_, 000_CD ×_NN 
          g_SYM for_IN 30_CD minutes_NNS at_IN 4_CD °_NN C_NNP and_CC the_DT
          supernatant_NN fraction_NN (_( cytosol_NN )_) was_VBD collected_VBN ._. After_IN the_DT
          removal_NN of_IN the_DT cytosolic_JJ fraction_NN ,_, the_DT nuclear_JJ pellet_NN was_VBD
          resuspended_JJ in_IN 1_CD ._. 5_CD ml_NN of_IN TEGT_NNP buffer_NN containing_VBG 0_CD ._. 4_CD M_NNP KCl_NNP
          and_CC incubated_JJ on_IN ice_NN for_IN 1_CD hour_NN with_IN intermittent_JJ
          vortexing_VBG ._. The_DT solubilized_JJ proteins_NNS were_VBD separated_JJ from_IN
          the_DT insoluble_JJ chromatin_NN by_IN centrifugation_NN at_IN 100_CD ,_, 000_CD ×_NN 
          g_SYM for_IN 30_CD minutes_NNS at_IN 4_CD °_NN C_NNP ._. The_DT
          supernatant_NN fraction_NN (_( nuclear_JJ extract_NN )_) was_VBD collected_VBN and_CC
          used_VBN immediately_RB for_IN experimentation_NN or_CC frozen_VBN at_IN
          -_: 80_CD °_NN C_NNP ._.
        
        
          Estrogen_NNP receptor_NN assay_NN
          The_DT concentration_NN of_IN unoccupied_JJ hERα_NN was_VBD determined_VBN by_IN
          ligand_NN binding_JJ analyses_NNS as_IN described_VBN previously_RB [_NN 22_CD 27_CD
          28_CD 29_CD 30_CD ]_NN ._. Briefly_NNP ,_, cytosols_NNS were_VBD incubated_JJ with_IN 5_CD nM_NN [_NN
          3_CD H_NNP ]_NN E_NNP 
          2_CD in_IN the_DT absence_NN (_( total_JJ binding_JJ )_) or_CC
          presence_NN (_( nonspecific_JJ binding_JJ )_) of_IN a_DT 1000_CD -_: fold_VB molar_NN
          excess_NN of_IN unlabeled_JJ DES_NNP for_IN 16_CD -_: 20_CD hours_NNS at_IN 4_CD °_NN C_NNP ._. Free_JJ
          radioactivity_NN was_VBD then_RB separated_JJ from_IN bound_VBN radioactivity_NN
          by_IN dextran-coated_JJ charcoal_NN (_( DCC_NNP )_) pellets_NNS ._. In_IN all_DT
          experiments_NNS ,_, nonspecific_JJ binding_JJ was_VBD determined_VBN and_CC
          subtracted_VBN from_IN total_JJ binding_JJ to_TO obtain_VB specific_JJ binding_JJ ._.
          The_DT binding_JJ data_NN were_VBD normalized_JJ in_IN femtomoles_NNS per_IN
          milligram_NN (_( fmol_NN /_NN mg_NN )_) of_IN cytosol_NN proteins_NNS ._. We_PRP chose_VBD a_DT
          positive_JJ cutoff_NN value_NN of_IN 10_CD fmol_NN /_NN mg_NN protein_NN for_IN hERα_NN [_NN 6_CD
          11_CD 12_CD 13_CD 31_CD 32_CD ]_NN ._.
        
        
          Synthesis_NNP and_CC purification_NN of_IN peptides_NNS
          We_PRP have_VBP previously_RB used_VBN sequence_NN specific_JJ peptides_NNS to_TO
          generate_VB site-directed_JJ monoclonal_NN and_CC polyclonal_NN
          antibodies_NNS [_NN 21_CD 22_CD 24_CD 25_CD 27_CD 28_CD ]_NN ._. Two_CD peptides_NNS ,_, NMT-_NNP 4_CD
          and_CC NMT-_NNP 5_CD ,_, were_VBD synthesized_JJ ,_, purified_JJ by_IN gel_NN filtration_NN
          and_CC analyzed_VBN by_IN HPLC_NNP ._. Analyses_NNS of_IN the_DT amino_JJ acid_NN
          composition_NN correlated_JJ well_RB with_IN the_DT primary_JJ sequence_NN ._.
          The_DT sequences_NNS of_IN these_DT peptides_NNS is_VBZ given_VBN in_IN Figure_NN
          1_CD A_DT ._.
        
        
          Peptide_NNP conjugation_NN and_CC immunization_NN
          Keyhole_NNP limpet_NN hemocyanin_NN (_( KLH_NNP )_) and_CC bovine_JJ serum_NN
          albumin_NN (_( BSA_NNP )_) were_VBD dissolved_VBN in_IN phosphate-buffered_JJ saline_NN
          (_( PBS_NNP )_) to_TO give_VB a_DT final_JJ concentration_NN of_IN 1_CD mg_NN /_NN ml_NN ._. Five_CD
          milligrams_NNS of_IN each_DT peptide_NN was_VBD then_RB dissolved_VBN in_IN 5_CD ml_NN of_IN
          the_DT KLH_NNP solution_NN or_CC BSA_NNP solution_NN ._. The_DT pH_NN of_IN the_DT mixtures_NNS
          was_VBD adjusted_VBN to_TO 9_CD ._. 0_CD with_IN 0_CD ._. 1_CD M_NNP LiOH_NNP ._. Coupling_NNP of_IN the_DT
          peptide_NN to_TO the_DT carrier_NN protein_NN was_VBD initiated_VBN by_IN drop_NN wise_JJ
          addition_NN of_IN 6_CD ._. 25_CD %_NN glutaraldehyde_NN to_TO achieve_VB a_DT final_JJ
          concentration_NN of_IN 1_CD %_NN ._. Each_DT mixture_NN was_VBD incubated_JJ at_IN 4_CD °_NN C_NNP
          for_IN one_CD hour_NN with_IN gentle_JJ agitation_NN ._. Each_DT mixture_NN was_VBD then_RB
          dialyzed_JJ extensively_RB against_IN four_CD changes_NNS of_IN PBS_NNP ._.
          Aliquots_NNP were_VBD taken_VBN after_IN dialysis_NN to_TO determine_VB
          efficiency_NN of_IN coupling_NN and_CC the_DT remaining_VBG dialyzed_JJ
          material_NN was_VBD stored_VBN at_IN -_: 80_CD °_NN C_NNP ._.
          New_NNP Zealand_NNP White_NNP female_JJ rabbits_NNS were_VBD obtained_VBN from_IN
          Pine_NNP Acre_NNP Rabbitry_NNP (_( Norton_NNP ,_, MA_NNP )_) ._. Prior_RB to_TO immunization_NN ,_,
          serum_NN was_VBD collected_VBN from_IN each_DT rabbit_NN by_IN bleeding_VBG through_IN
          the_DT ear_NN artery_NN and_CC this_DT was_VBD designated_VBN as_IN pre-immune_JJ
          serum_NN ._. Each_DT animal_NN was_VBD immunized_JJ by_IN subcutaneous_JJ
          injection_NN at_IN multiple_JJ sites_NNS along_IN the_DT back_NN with_IN a_DT total_NN
          of_IN 1_CD ml_NN of_IN an_DT emulsion_NN made_VBN by_IN mixing_VBG equal_JJ volumes_NNS of_IN
          complete_JJ Freund_NNP 's_POS adjuvant_NN and_CC KLH-conjugated_NNP peptide_NN ._.
          The_DT final_JJ emulsion_NN contained_VBD 500_CD μg_NN /_NN ml_NN of_IN the_DT desired_VBN
          peptide_NN ._. After_IN 3_CD weeks_NNS ,_, the_DT animals_NNS were_VBD boosted_VBN with_IN the_DT
          antigen_NN in_IN incomplete_JJ Freund_NNP 's_POS adjuvant_NN ._. Two_CD weeks_NNS after_IN
          the_DT booster_NN shots_NNS the_DT animals_NNS were_VBD bled_VBD ,_, the_DT sera_NN were_VBD
          collected_VBN and_CC tested_VBN for_IN the_DT presence_NN of_IN anti-peptide_JJ
          antibodies_NNS by_IN enzyme-linked_JJ immunosorbent_NN assay_NN
          (_( ELISA_NNP )_) ._.
        
        
          RNA_NNP preparation_NN and_CC northern_JJ blot_NN analyses_NNS
          Total_NNP RNA_NNP from_IN MCF-_NNP 7_CD cells_NNS and_CC human_JJ breast_NN tumors_NNS was_VBD
          prepared_VBN as_IN described_VBN [_NN 33_CD ]_NN ._. Total_NNP RNA_NNP was_VBD
          electrophoresed_JJ on_IN 1_CD %_NN formaldehyde_NN /_NN MOPS_NNP agarose_NN gels_NNS and_CC
          transferred_VBN onto_IN nylon-reinforced_JJ nitrocellulose_NN
          membranes_NNS ._. Northern_JJ blot_NN analysis_NN was_VBD carried_VBN out_IN using_VBG
          double-stranded_JJ DNA_NNP probes_NNS labeled_VBN to_TO a_DT specific_JJ activity_NN
          of_IN 10_CD 8_CD -_: 10_CD 9_CD cpm_NN /_NN μg_NN with_IN α-_NN [_NN 32_CD P_NN ]_NN CTP_NNP using_VBG T_NN 7_CD DNA_NNP
          polymerase_NN and_CC random_JJ primers_NNS ._. Hybridization_NNP was_VBD carried_VBN
          out_RB at_IN 67_CD °_NN C_NNP for_IN 2_CD hours_NNS in_IN Quickhyb_NNP solution_NN (_( Stratagene_NNP ,_,
          La_NNP Jolla_NNP ,_, CA_NNP )_) ._. Membranes_NNP were_VBD exposed_VBN to_TO Hyperfilm_NNP
          (_( Amersham_NNP ,_, Arlington_NNP Heights_NNP ,_, IL_NNP )_) for_IN 24_CD hours_NNS at_IN -_: 70_CD °_NN C_NNP
          following_VBG low_JJ (_( 2_CD X_NNP SSC_NNP ,_, 0_CD ._. 1_CD %_NN SDS_NNP ,_, 25_CD °_NN C_NNP )_) and_CC high_JJ (_( 0_CD ._. 2_LS X_NNP
          SSC_NNP ,_, 0_CD ._. 1_CD %_NN SDS_NNP ,_, 65_CD °_NN C_NNP )_) stringency_NN washes_NNS ._.
          The_DT probe_NN used_VBN for_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbanalysis_NNS was_VBD a_DT 499_CD bp_NN
          SacI_NNP /_NN BglII_NNP fragment_NN representing_VBG the_DT unique_JJ carboxyl_NN
          terminus_JJ of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrb_NN [_NN 13_CD ]_NN ._. This_DT probe_NN was_VBD
          utilized_JJ to_TO prevent_VB cross-hybridization_JJ with_IN other_JJ
          homologous_RB RNA_NNP binding_JJ proteins_NNS ._. A_DT 545_CD bp_NN HindIII_NNP /_NN Xbal_NNP
          fragment_NN of_IN human_JJ glyceraldehyde-_NN 3_CD -_: phosphate_NN
          dehydrogenase_NN (_( GAPDH_NNP )_) was_VBD utilized_JJ as_IN a_DT probe_NN to_TO
          normalize_VB for_IN RNA_NNP loading_NN [_NN 34_CD ]_NN ._.
        
        
          Ribonuclease_NNP protection_NN assays_NNS
          Ribonuclease_NNP protection_NN assays_NNS were_VBD performed_VBN using_VBG
          the_DT RPA_NNP III_NNP Ribonuclease_NNP Protection_NNP Assay_NNP Kit_NNP from_IN Ambion_NNP
          (_( Austin_NNP ,_, TX_NNP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS
          specifications_NNS ._. RNA_NNP was_VBD isolated_VBN and_CC prepared_VBN as_IN
          described_VBN above_IN ._. A_DT 499_CD bp_NN nmt_NN 55_CD /_NN p_NN 54_CD nrbfragment_NN was_VBD
          transcribed_JJ with_IN T_NN 7_CD RNA_NNP polymerase_NN in_IN the_DT presence_NN of_IN α-_NN [_NN
          32_CD P_NN ]_NN CTP_NNP and_CC non-radioactive_JJ nucleotides_NNS to_TO generate_VB an_DT
          antisense_NN probe_NN (_( specific_JJ activity_NN of_IN 10_CD 8_CD -_: 10_CD 9_CD cpm_NN /_NN μg_NN )_)
          or_CC SP_NNP 6_CD RNA_NNP polymerase_NN in_IN the_DT presence_NN of_IN non-labeled_JJ
          nucleotides_NNS to_TO generate_VB a_DT sense_NN probe_NN (_( control_NN )_) ._. Sample_NNP
          RNA_NNP and_CC the_DT antisense_NN probe_NN were_VBD mixed_JJ and_CC
          co-precipitated_JJ with_IN 0_CD ._. 5_CD M_NNP ammonium_NN acetate_NN ._. Samples_NNP were_VBD
          hybridized_JJ for_IN 18_CD hours_NNS in_IN acetate_NN /_NN citrate_NN buffer_NN ,_, pH_NN
          6_CD ._. 8_CD ,_, at_IN 45_CD °_NN C_NNP ._. The_DT hybridization_NN product_NN was_VBD digested_VBN with_IN
          an_DT RNase_NNP A_DT /_NN T_NN 1_CD mixture_NN ._. Following_VBG digestion_NN ,_, RNase_NNP was_VBD
          inactivated_JJ and_CC hybridized_JJ RNA_NNP was_VBD precipitated_VBD according_VBG
          to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._. Precipitated_NNP samples_NNS
          were_VBD resuspended_JJ and_CC analyzed_VBN by_IN gel_NN electrophoresis_NNS on_IN
          5_CD %_NN urea-polyacrylamide_JJ denaturing_VBG gels_NNS ._. Following_VBG
          electrophoresis_NNS ,_, gels_NNS were_VBD dried_VBN for_IN 2_CD hours_NNS at_IN 80_CD °_NN C_NNP and_CC
          subjected_VBN to_TO autoradiography_NN for_IN 24_CD hours_NNS at_IN -_: 70_CD °_NN C_NNP ._.
          Century_NN markers_NNS were_VBD radiolabeled_JJ according_VBG to_TO the_DT
          manufacturer_NN 's_POS instructions_NNS and_CC used_VBN as_IN molecular_JJ weight_NN
          markers_NNS ._.
        
        
          Electrophoresis_NNP and_CC western_JJ blot_NN analyses_NNS
          Polyacrylamide_NNP gel_NN electrophoresis_NNS and_CC Western_JJ blot_NN
          analyses_NNS were_VBD performed_VBN as_IN described_VBN [_NN 13_CD 23_CD ]_NN ._. Briefly_NNP ,_,
          samples_NNS were_VBD electrophoresed_JJ on_IN 10_CD %_NN resolving_VBG sodium_NN
          dodecyl_NN sulphate-polyacrylamide_JJ gels_NNS (_( SDS_NNP /_NN PAGE_NNP )_) according_VBG
          to_TO the_DT method_NN of_IN Laemmli_NNP [_NN 35_CD ]_NN ._. Proteins_NNPS were_VBD then_RB
          electrotransferred_JJ onto_IN nitrocellulose_NN membranes_NNS and_CC the_DT
          membranes_NNS were_VBD incubated_JJ in_IN TBST_NNP buffer_NN containing_VBG 5_CD %_NN
          nonfat_JJ dry_JJ milk_NN for_IN 1_CD hour_NN to_TO block_VB nonspecific_JJ protein_NN
          binding_JJ ._. Membranes_NNP were_VBD incubated_JJ with_IN primary_JJ
          antibodies_NNS ,_, at_IN various_JJ dilutions_NNS ,_, for_IN 1_CD hour_NN and_CC then_RB
          washed_VBN three_CD times_NNS with_IN TBST_NNP ,_, 10_CD minutes_NNS each_DT ._.
          Nitrocellulose_NNP membranes_NNS were_VBD then_RB incubated_JJ with_IN the_DT
          appropriate_JJ corresponding_JJ horseradish_NN
          peroxidase-conjugated_JJ secondary_JJ antibody_NN for_IN 1_CD hour_NN and_CC
          washed_VBN as_IN above_IN ._. Antibody-protein_NNP interactions_NNS were_VBD
          detected_VBN using_VBG enhanced_JJ chemiluminescence_NN (_( ECL_NNP )_) (_( Pierce_NNP ,_,
          Rockford_NNP ,_, IL_NNP )_) and_CC autoradiography_NN ._.
        
        
          Immunohistochemistry_NNP
          Formalin-fixed_NNP ,_, paraffin-embedded_JJ blocks_NNS of_IN human_JJ
          breast_NN tissue_NN were_VBD re-cut_JJ at_IN a_DT thickness_NN of_IN 4_CD μm_NN ,_, and_CC
          consecutive_JJ sections_NNS were_VBD stained_JJ with_IN Gill_NNP 's_POS hematoxylin_NN
          and_CC eosin_NN (_( H_NNP &_CC E_NNP )_) [_NN 23_CD ]_NN ._. Immunohistochemical_NNP assays_NNS
          were_VBD performed_VBN using_VBG a_DT modification_NN of_IN the_DT
          antigen-retrieval_JJ technique_NN based_VBN on_IN microwave_NN exposure_NN ._.
          Unless_IN stated_VBN otherwise_RB ,_, all_DT incubations_NNS were_VBD at_IN 37_CD °_NN C_NNP in_IN
          a_DT humidity_NN chamber_NN ,_, followed_VBN by_IN two_CD PBS_NNP plus_CC Triton_NNP X-_NNP 100_CD
          (_( 1_CD :_: 500_CD )_) washes_NNS ,_, 2_CD minutes_NNS each_DT ._. Endogenous_NNP peroxidase_NN
          activity_NN was_VBD quenched_JJ using_VBG a_DT 3_CD %_NN hydrogen_NN
          peroxide_NN /_NN methanol_NN solution_NN for_IN 30_CD minutes_NNS at_IN 25_CD °_NN C_NNP ._. This_DT
          was_VBD followed_VBN by_IN antigen_NN retrieval_NN and_CC subsequent_JJ
          incubation_NN in_IN blocking_VBG reagent_NN (_( 1_CD :_: 50_CD normal_JJ horse_NN serum_NN )_)
          for_IN 20_CD minutes_NNS ._. Anti-h_NNP ERα_NNP monoclonal_NN antibody_NN EVG_NNP F_NN 9_CD and_CC
          anti-h_JJ PR_NNP monoclonal_NN antibody_NN 4_CD ._. 14_CD were_VBD diluted_VBN 1_CD :_: 200_CD and_CC
          incubated_JJ for_IN 30_CD minutes_NNS at_IN 37_CD °_NN C_NNP ._. Anti-nmt_NNP 55_CD /_NN p_NN 54_CD
          nrbpolyclonal_NN antibodies_NNS ,_, NMT-_NNP 4_CD and_CC NMT-_NNP 5_CD ,_, were_VBD diluted_VBN
          1_CD :_: 2500_CD and_CC incubated_JJ for_IN 2_CD hours_NNS at_IN 37_CD °_NN C_NNP ._. Non-immune_NNP
          mouse_NN IgG_NNP was_VBD used_VBN as_IN a_DT negative_JJ control_NN antibody_NN ._.
          Sections_NNP were_VBD rinsed_JJ and_CC incubated_JJ with_IN secondary_JJ
          antibody_NN (_( rabbit_NN anti-mouse_JJ IgG_NNP ,_, biotinylated_JJ or_CC swine_NNS
          anti-rabbit_JJ IgG_NNP ,_, biotinylated_JJ )_) for_IN 30_CD minutes_NNS followed_VBN by_IN
          a_DT 30_CD minute_NN incubation_NN in_IN Streptavidin_NNP solution_NN ,_, using_VBG
          DAKO_NNP 's_POS Quick_NNP Staining_NNP LSAB_NNP Kit_NNP (_( DAKO_NNP Corp_NNP ,_, Carpinteria_NNP ,_,
          CA_NNP )_) ._. To_TO visualize_VB antibody_NN binding_JJ ,_, tissue_NN sections_NNS were_VBD
          incubated_JJ for_IN 10_CD minutes_NNS in_IN 3_CD ,_, 3_CD '_POS -_: diaminobenzidine_NN (_( DAB_NNP )_)
          at_IN 25_CD °_NN C_NNP ._. Sections_NNP were_VBD then_RB rinsed_JJ in_IN distilled_VBN water_NN and_CC
          counterstained_JJ for_IN 1_CD minute_NN in_IN Gill_NNP 's_POS hematoxylin_NN ._. Slides_NNS
          were_VBD analyzed_VBN by_IN standard_JJ light_JJ microscopy_NN ._.
        
      
      
        Results_NNS
        
          Analysis_NNP of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbmRNA_NN in_IN ER_NNP +_NN and_CC ER-_NNP human_JJ
          breast_NN tumors_NNS
          We_PRP have_VBP previously_RB shown_VBN that_DT nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN was_VBD
          expressed_VBN in_IN most_JJS ER_NNP +_NN /_NN PR_NNP +_NN human_JJ breast_NN tumors_NNS but_CC was_VBD
          undetectable_JJ in_IN ER-_NNP /_NN PR-_NNP human_JJ breast_NN tumors_NNS [_NN 13_CD ]_NN ._.
          Since_IN loss_NN of_IN hERα_NN expression_NN is_VBZ associated_VBN with_IN poor_JJ
          prognosis_NN and_CC continued_VBD expression_NN of_IN hERα_NN is_VBZ associated_VBN
          with_IN disease-free_JJ survival_NN and_CC correlates_NNS well_RB with_IN tumor_NN
          differentiation_NN state_NN ,_, we_PRP wanted_VBD to_TO investigate_VB the_DT
          regulation_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbexpression_NN ._. To_TO test_VB the_DT
          possibility_NN that_DT nmt_NN 55_CD /_NN p_NN 54_CD nrbmay_NN be_VB transcriptionally_RB
          downregulated_JJ in_IN ER-_NNP tumors_NNS ,_, we_PRP analyzed_VBD mRNA_NN levels_NNS from_IN
          a_DT series_NN of_IN human_JJ breast_NN tumors_NNS utilizing_VBG Northern_NNP blot_NN
          analyses_NNS and_CC ribonuclease_NN protection_NN assays_NNS ._.
          Figure_NN 2_CD shows_VBZ Northern_NNP blot_NN analysis_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD
          nrbmRNA_NN expression_NN in_IN 12_CD human_JJ breast_NN tumors_NNS ._. MCF-_NNP 7_CD cells_NNS
          (_( Lane_NNP M_NNP )_) ,_, used_VBN as_IN a_DT control_NN ,_, express_VBP an_DT abundant_JJ 2_CD ._. 6_CD kb_NN
          mRNA_NN transcript_NN for_IN nmt_NN 55_CD /_NN p_NN 54_CD nrb_NN ._. nmt_NN 55_CD /_NN p_NN 54_CD
          nrbtranscripts_NNS were_VBD detected_VBN at_IN varying_VBG levels_NNS in_IN both_DT
          ER_NNP +_NN and_CC ER-_NNP tumors_NNS ._. mRNA_NN transcript_NN was_VBD expressed_VBN at_IN high_JJ
          levels_NNS (_( lanes_NNS 2_CD ,_, 3_CD ,_, 5_CD ,_, 9_CD ,_, 11_CD and_CC 12_CD )_) moderate_JJ levels_NNS
          (_( lanes_NNS 2_CD ,_, 7_CD and_CC 10_CD )_) or_CC low_JJ levels_NNS (_( lanes_NNS 1_CD ,_, 4_CD and_CC 8_CD )_) ._. The_DT
          tumor_NN sample_NN in_IN lane_NN 6_CD was_VBD degraded_JJ and_CC was_VBD not_RB analyzed_VBN
          further_RB ._. These_DT different_JJ nmt_NN 55_CD /_NN p_NN 54_CD nrbmRNA_NN levels_NNS were_VBD
          not_RB due_JJ to_TO differential_NN RNA_NNP loading_NN ,_, as_IN GAPDH_NNP levels_NNS were_VBD
          similar_JJ in_IN all_DT tumor_NN samples_NNS ._. These_DT results_NNS suggest_VBP that_DT
          nmt_NN 55_CD /_NN p_NN 54_CD nrbmRNA_NN transcripts_NNS are_VBP expressed_VBN at_IN various_JJ
          levels_NNS ._. It_PRP also_RB suggested_VBD that_DT nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN
          expression_NN in_IN some_DT breast_NN tumors_NNS does_VBZ not_RB correlate_VBP with_IN
          nmt_NN 55_CD /_NN p_NN 54_CD nrbmRNA_NN expression_NN ._. Specifically_RB ,_, the_DT decreased_VBN
          nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN expression_NN observed_VBD in_IN ER-_NNP human_JJ
          breast_NN tumors_NNS may_MD not_RB be_VB attributed_VBN to_TO transcriptional_NN
          regulation_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbmRNA_NN since_IN mRNA_NN expression_NN in_IN
          ER-_NNP tumors_NNS is_VBZ not_RB universally_RB decreased_VBD ._.
          To_TO confirm_VB these_DT observations_NNS ,_, ribonuclease_NN protection_NN
          assay_NN was_VBD utilized_JJ to_TO analyze_VB a_DT set_NN of_IN different_JJ human_JJ
          breast_NN tumors_NNS ._. As_IN shown_VBN in_IN Figure_NN 3_CD ,_, all_DT human_JJ tumor_NN
          samples_NNS expressed_VBD nmt_NN 55_CD /_NN p_NN 54_CD nrbmRNA_NN transcript_NN ._. nmt_NN 55_CD /_NN p_NN 54_CD
          nrbmRNA_NN was_VBD not_RB detected_VBN in_IN calf_NN uterine_NN tissue_NN ._. This_DT was_VBD
          expected_VBN since_IN the_DT nmt_NN 55_CD /_NN p_NN 54_CD nrbprobe_NN utilized_JJ for_IN
          detection_NN is_VBZ of_IN human_JJ origin_NN and_CC calf_NN uterus_NN tissue_NN
          expresses_VBZ a_DT different_JJ transcript_NN for_IN nmt_NN 55_CD /_NN p_NN 54_CD nrb_NN ._. This_DT
          prevents_VBZ high_JJ fidelity_NN hybridization_NN between_IN the_DT probe_NN
          and_CC the_DT mRNA_NN allowing_VBG complete_JJ mRNA_NN probe_NN digestion_NN ._.
          Based_VBN on_IN the_DT data_NNS presented_VBN in_IN Figures_NNS 2_CD and_CC 3_CD ,_, it_PRP appears_VBZ
          that_DT nmt_NN 55_CD /_NN p_NN 54_CD nrbmRNA_NN is_VBZ expressed_VBN independent_JJ of_IN tumor_NN
          hormonal_NN status_NN suggesting_VBG that_DT nmt_NN 55_CD /_NN p_NN 54_CD nrbmRNA_NN is_VBZ not_RB
          regulated_VBN by_IN hERα_NN ._. These_DT results_NNS ,_, together_RB with_IN those_DT
          reported_VBN previously_RB [_NN 13_CD ]_NN ,_, further_JJ suggest_VBP that_WDT
          decreased_VBN expression_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN in_IN ER-_NNP human_JJ
          breast_NN tumors_NNS is_VBZ likely_JJ a_DT post-transcriptional_JJ event_NN ._.
        
        
          Immunochemical_NNP detection_NN of_IN multiple_JJ nmt_NN 55_CD /_NN p_NN 54_CD
          nrbprotein_NN isoforms_NNS in_IN human_JJ breast_NN tumors_NNS
          Since_IN there_EX was_VBD no_DT apparent_JJ nmt_NN 55_CD /_NN p_NN 54_CD nrbmRNA_NN
          regulation_NN in_IN ER_NNP +_NN or_CC ER-_NNP human_JJ breast_NN tumors_NNS ,_, it_PRP was_VBD
          possible_JJ that_DT monoclonal_NN antibody_NN NMT-_NNP 1_CD may_MD not_RB detect_VB
          the_DT presence_NN of_IN potential_JJ multiple_JJ isoforms_NNS of_IN nmt_NN 55_CD /_NN p_NN 54_CD
          nrbprotein_NN especially_RB in_IN ER-_NNP tumors_NNS ._. This_DT necessitated_VBD
          the_DT development_NN of_IN domain_NN specific_JJ antibodies_NNS ._. To_TO this_DT
          end_NN ,_, two_CD peptides_NNS were_VBD synthesized_JJ and_CC purified_JJ based_VBN on_IN
          selected_VBN sequences_NNS in_IN the_DT subdomains_NNS of_IN human_JJ nmt_NN 55_CD /_NN p_NN 54_CD
          nrb_NN (_( Figure_NN 1_CD A_DT )_) ._. These_DT selected_VBN peptides_NNS were_VBD referred_VBN to_TO
          as_IN NMT-_NNP 4_CD and_CC NMT-_NNP 5_CD and_CC represent_VB sequences_NNS 56_CD -_: 72_CD and_CC
          371_CD -_: 386_CD of_IN human_JJ nmt_NN 55_CD /_NN p_NN 54_CD nrb_NN ,_, respectively_RB (_( Figure_NN 1_CD A_DT )_) ._.
          Polyclonal_NNP antibodies_NNS were_VBD developed_VBN against_IN these_DT
          peptides_NNS ;_: polyclonal_NN antibody_NN NMT-_NNP 4_CD recognized_VBD a_DT sequence_NN
          in_IN the_DT amino_JJ terminal_NN region_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrband_NN
          polyclonal_NN antibody_NN NMT-_NNP 5_CD recognized_VBD a_DT sequence_NN in_IN a_DT
          mid-region_JJ of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrb_NN (_( Figure_NN 1_CD B_NNP )_) ._.
          Figure_NN 4_CD shows_VBZ the_DT binding_JJ of_IN polyclonal_NN antibodies_NNS
          NMT-_NNP 4_CD and_CC NMT-_NNP 5_CD to_TO a_DT protein_NN with_IN an_DT estimated_VBN molecular_JJ
          weight_NN of_IN 55_CD kDa_NN (_( lanes_NNS 3_CD and_CC 5_CD respectively_RB )_) ._. Pre-immune_NNP
          sera_NN detected_VBD no_DT specific_JJ protein_NN in_IN the_DT 55_CD kDa_NN range_NN
          (_( lanes_NNS 1_CD and_CC 2_LS )_) ._. Specificity_NNP of_IN the_DT polyclonal_NN antibodies_NNS
          was_VBD assessed_VBN by_IN pre-incubation_JJ with_IN the_DT appropriate_JJ
          immunogenic_JJ free_JJ peptides_NNS ._. As_IN shown_VBN in_IN Figure_NN 4_CD (_( lanes_NNS 4_CD
          and_CC 6_CD )_) ,_, the_DT antigenic_JJ peptides_NNS competed_VBN effectively_RB for_IN
          the_DT binding_VBG of_IN the_DT antibodies_NNS to_TO the_DT protein_NN indicating_VBG
          that_IN these_DT antibodies_NNS are_VBP specific_JJ ._. Complete_JJ displacement_NN
          was_VBD not_RB seen_VBN in_IN Lane_NNP 6_CD which_WDT was_VBD due_JJ to_TO high_JJ titer_NN of_IN the_DT
          antibody_NN ._. Incubation_NNP of_IN NMT-_NNP 5_CD antibody_NN with_IN a_DT higher_JJR
          concentration_NN of_IN free_JJ immunogenic_JJ NMT-_NNP 5_CD peptide_NN resulted_VBD
          in_IN complete_JJ displacement_NN (_( results_NNS not_RB shown_VBN )_) ._. These_DT
          results_NNS indicate_VBP that_IN the_DT anti-peptide_JJ polyclonal_NN
          antibodies_NNS ,_, NMT-_NNP 4_CD and_CC NMT-_NNP 5_CD ,_, detect_VBP this_DT 55_CD kDa_NN protein_NN
          with_IN high_JJ specificity_NN and_CC high_JJ affinity_NN ._.
          Since_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbbelongs_NNS to_TO a_DT family_NN of_IN RNA_NNP binding_JJ
          proteins_NNS with_IN conserved_JJ domains_NNS ,_, it_PRP was_VBD possible_JJ that_IN the_DT
          polyclonal_NN antibodies_NNS NMT-_NNP 4_CD and_CC NMT-_NNP 5_CD were_VBD detecting_VBG a_DT
          protein_NN with_IN a_DT similar_JJ molecular_JJ weight_NN ._. To_TO investigate_VB
          this_DT possibility_NN ,_, we_PRP carried_VBD out_IN immunoprecipitation_NN
          assays_NNS of_IN MCF-_NNP 7_CD nuclear_JJ extract_NN with_IN a_DT series_NN of_IN
          antibodies_NNS ,_, and_CC immunoblotted_JJ with_IN the_DT same_JJ series_NN of_IN
          antibodies_NNS ._.
          Figure_NN 5_CD shows_VBZ MCF-_NNP 7_CD nuclear_JJ extract_NN immunoprecipitated_JJ
          with_IN monoclonal_NN antibody_NN NMT-_NNP 1_CD ,_, polyclonal_NN antibody_NN
          NMT-_NNP 4_CD ,_, polyclonal_NN antibody_NN NMT-_NNP 5_CD or_CC monoclonal_NN antibody_NN
          EVG_NNP F_NNP 9_CD ._. The_DT immunoprecipitate_NN samples_NNS were_VBD then_RB separated_VBN
          by_IN SDS_NNP /_NN PAGE_NNP and_CC immunoblotted_JJ with_IN monoclonal_NN antibody_NN
          NMT-_NNP 1_CD (_( top_JJ panel_NN )_) ,_, polyclonal_NN antibody_NN NMT-_NNP 4_CD (_( middle_JJ
          panel_NN )_) or_CC polyclonal_NN antibody_NN NMT-_NNP 5_CD (_( bottom_JJ panel_NN )_) ._. The_DT
          results_NNS show_VBP that_IN this_DT 55_CD kDa_NN protein_NN is_VBZ detected_VBN
          regardless_RB of_IN which_WDT antibody_NN is_VBZ used_VBN for_IN
          immunoprecipitation_NN or_CC immunoblotting_VBG ._. Since_IN monoclonal_NN
          antibody_NN NMT-_NNP 1_CD is_VBZ specific_JJ for_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN [_NN 13_CD
          ]_NN ,_, the_DT results_NNS suggest_VBP that_IN polyclonal_NN antibodies_NNS NMT-_NNP 4_CD
          and_CC NMT-_NNP 5_CD are_VBP specific_JJ to_TO nmt_NN 55_CD /_NN p_NN 54_CD nrband_NN do_VBP not_RB detect_VB
          related_VBN RNA_NNP binding_JJ proteins_NNS ._. nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN was_VBD
          not_RB detected_VBN in_IN the_DT anti-h_JJ ERα_NNP monoclonal_NN antibody_NN EVG_NNP F_NNP 9_CD
          immunoprecipitation_NN sample_NN (_( negative_JJ control_NN )_) ._. Monoclonal_NNP
          antibody_NN NMT-_NNP 1_CD and_CC polyclonal_NN antibodies_NNS NMT-_NNP 4_CD and_CC NMT-_NNP 5_CD
          also_RB detect_VB bacterially_RB expressed_VBD partially_RB purified_JJ
          nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN (_( results_NNS not_RB shown_VBN )_) ._. These_DT results_NNS
          indicate_VBP that_DT monoclonal_NN antibody_NN NMT-_NNP 1_CD (_( carboxyl_NN
          terminal_NN )_) and_CC the_DT polyclonal_NN antibodies_NNS NMT-_NNP 4_CD (_( amino_JJ
          terminal_NN )_) and_CC NMT-_NNP 5_CD (_( mid-region_JJ )_) detect_VB nmt_NN 55_CD /_NN p_NN 54_CD
          nrbprotein_NN with_IN high_JJ affinity_NN and_CC high_JJ specificity_NN ._.
          Figure_NN 6_CD shows_VBZ Western_JJ blot_NN analysis_NN of_IN nuclear_JJ
          extracts_NNS from_IN 10_CD human_JJ breast_NN tumor_NN immunoblotted_JJ with_IN
          polyclonal_NN antibodies_NNS NMT-_NNP 4_CD (_( top_JJ panel_NN )_) ,_, NMT-_NNP 5_CD (_( middle_JJ
          panel_NN )_) and_CC monoclonal_NN antibody_NN NMT-_NNP 1_CD (_( bottom_JJ panel_NN )_) ._. No_DT
          antibodies_NNS detected_VBD nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN in_IN ER-_NNP human_JJ
          breast_NN tumors_NNS (_( lanes_NNS 1_CD -_: 5_LS )_) confirming_VBG previous_JJ
          observations_NNS [_NN 13_CD ]_NN ._. Monoclonal_NNP antibody_NN NMT-_NNP 1_CD and_CC
          polyclonal_NN antibody_NN NMT-_NNP 5_CD detect_VB nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN in_IN
          all_DT ER_NNP +_NN tumor_NN samples_NNS (_( lanes_NNS 5_CD -_: 10_CD )_) ,_, albeit_IN at_IN varying_VBG
          levels_NNS ._. Interestingly_RB however_RB ,_, polyclonal_NN antibody_NN NMT-_NNP 4_CD
          detected_VBD nmt_NN 55_CD /_NN p_NN 54_CD nrbin_NN only_RB 3_CD out_IN of_IN 5_CD ER_NNP +_NN tumors_NNS ._.
          These_DT results_NNS have_VBP been_VBN reproduced_VBD in_IN the_DT nuclear_JJ
          extracts_NNS of_IN approximately_RB forty_NN human_JJ breast_NN tumors_NNS
          suggesting_VBG that_IN there_EX is_VBZ an_DT alteration_NN or_CC modification_NN in_IN
          the_DT amino_JJ terminal_NN domain_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbthat_NN prevents_VBZ
          polyclonal_NN antibody_NN NMT-_NNP 4_CD from_IN binding_JJ to_TO nmt_NN 55_CD /_NN p_NN 54_CD
          nrbprotein_NN ._. The_DT observations_NNS made_VBN here_RB further_JJ suggest_VBP
          the_DT presence_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbvariants_NNS in_IN a_DT subset_NN of_IN ER_NNP +_NN
          human_JJ breast_NN tumors_NNS ._.
          Detection_NNP of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbby_NN Western_JJ blot_NN analyses_NNS
          requires_VBZ tumor_NN pulverization_NN ,_, homogenization_NN ,_,
          fractionation_NN and_CC the_DT preparation_NN of_IN cellular_JJ extracts_NNS ._.
          These_DT manipulations_NNS may_MD result_VB in_IN biochemical_JJ alterations_NNS
          of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbduring_VBG processing_NN ._. To_TO insure_VB that_IN this_DT
          observation_NN was_VBD not_RB the_DT result_NN of_IN experimental_JJ
          manipulation_NN ,_, and_CC indeed_RB the_DT nmt_NN 55_CD /_NN p_NN 54_CD nrbvariants_NNS
          detected_VBD with_IN polyclonal_NN antibody_NN NMT-_NNP 5_CD and_CC monoclonal_NN
          antibody_NN NMT-_NNP 1_CD but_CC not_RB polyclonal_NN antibody_NN NMT-_NNP 4_CD were_VBD
          also_RB expressed_VBN in_IN intact_JJ cells_NNS ,_, we_PRP utilized_JJ
          immunohistochemical_JJ analyses_NNS in_IN human_JJ breast_NN tumor_NN tissue_NN
          sections_NNS ._. Further_RB ,_, immunohistochemistry_NN permits_VBZ the_DT
          assessment_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbsubcellular_NN localization_NN and_CC
          distribution_NN within_IN human_JJ breast_NN tumors_NNS ._.
          Figure_NN 7_CD shows_VBZ immunohistochemical_JJ analyses_NNS of_IN a_DT human_JJ
          breast_NN tumor_NN using_VBG hERα_NN ,_, hPR_NN and_CC nmt_NN 55_CD /_NN p_NN 54_CD nrbspecific_JJ
          antibodies_NNS ._. Tissue_NNP sections_NNS stained_JJ positively_RB with_IN
          monoclonal_NN antibodies_NNS EVG_NNP F_NNP 9_CD (_( Panel_NNP A_DT )_) and_CC 4_CD ._. 14_CD (_( Panel_NNP B_NNP )_)
          showing_VBG the_DT expression_NN of_IN hERα_NN and_CC hPR_NN ,_, respectively_RB ._.
          Positive_JJ staining_VBG with_IN polyclonal_NN antibodies_NNS NMT-_NNP 4_CD (_( Panel_NNP
          C_NNP )_) and_CC NMT-_NNP 5_CD (_( Panel_NNP D_NNP )_) showed_VBD the_DT presence_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD
          nrb_NN ._. Figure_NN 8_CD represents_VBZ a_DT tumor_NN which_WDT exhibited_VBN positive_JJ
          staining_VBG for_IN hERα_NN (_( Panel_NNP A_DT )_) ,_, hPR_NN (_( Panel_NNP B_NNP )_) ,_, and_CC nmt_NN 55_CD /_NN p_NN 54_CD
          nrbwhen_NN utilizing_VBG polyclonal_NN antibody_NN NMT-_NNP 5_CD (_( Panel_NNP D_NNP )_) ._.
          However_RB ,_, this_DT tumor_NN did_VBD not_RB stain_VB positive_JJ for_IN nmt_NN 55_CD /_NN p_NN 54_CD
          nrbwhen_NN polyclonal_NN antibody_NN NMT-_NNP 4_CD was_VBD utilized_JJ (_( Panel_NNP C_NNP )_) ._.
          Similar_JJ results_NNS have_VBP been_VBN observed_VBN in_IN sixteen_NN different_JJ
          human_JJ breast_NN tumor_NN tissue_NN sections_NNS ._. The_DT
          immunohistochemistry_NN data_NN confirm_VBP the_DT results_NNS obtained_VBN by_IN
          Western_JJ blot_NN analyses_NNS ,_, suggesting_VBG that_DT nmt_NN 55_CD /_NN p_NN 54_CD
          nrbprotein_NN is_VBZ expressed_VBN in_IN various_JJ isoforms_NNS in_IN a_DT subset_NN
          of_IN ER_NNP +_NN human_JJ breast_NN tumors_NNS ._. The_DT nature_NN of_IN the_DT alteration_NN
          or_CC modification_NN in_IN the_DT amino-terminal_JJ region_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD
          nrb_NN ,_, which_WDT prevents_VBZ the_DT detection_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbby_NN
          polyclonal_NN antibody_NN NMT-_NNP 4_CD by_IN Western_JJ blot_NN and_CC
          immunohistochemical_JJ analyses_NNS ,_, remains_VBZ to_TO be_VB
          determined_VBN ._.
        
      
      
        Discussion_NNP
        We_PRP have_VBP previously_RB investigated_VBN nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN
        expression_NN in_IN human_JJ breast_NN tumors_NNS and_CC observed_VBD a_DT
        statistically_RB significant_JJ association_NN between_IN decreased_VBD
        nmt_NN 55_CD /_NN p_NN 54_CD nrbexpression_NN ,_, loss_NN of_IN hERα_NN and_CC hPR_NN and_CC increased_VBN
        tumor_NN size_NN [_NN 13_CD ]_NN ._. It_PRP is_VBZ possible_JJ that_WDT decreased_VBD nmt_NN 55_CD /_NN p_NN 54_CD
        nrbexpression_NN represents_VBZ poor_JJ tumor_NN differentiation_NN ,_,
        increased_VBN tumor_NN growth_NN and_CC metastases_NNS since_IN reduced_VBN or_CC
        absent_JJ hERα_NN expression_NN and_CC function_NN correlates_NNS with_IN poor_JJ
        tumor_NN differentiation_NN [_NN 11_CD 36_CD ]_NN and_CC tumor_NN size_NN is_VBZ a_DT strong_JJ
        indicator_NN of_IN tumor_NN progression_NN [_NN 37_CD ]_NN ._. Here_RB we_PRP
        investigated_VBD nmt_NN 55_CD /_NN p_NN 54_CD nrbmRNA_NN expression_NN using_VBG Northern_NNP
        blot_NN analyses_NNS and_CC ribonuclease_NN protection_NN assays_NNS to_TO
        determine_VB if_IN the_DT reduction_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN
        expression_NN was_VBD the_DT result_NN of_IN transcriptional_NN regulation_NN ._.
        mRNA_NN transcripts_NNS for_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbshowed_JJ similar_JJ expression_NN
        in_IN human_JJ breast_NN tumors_NNS and_CC were_VBD not_RB related_VBN to_TO hERα_NN
        expression_NN ._. These_DT results_NNS suggest_VBP that_IN the_DT regulation_NN of_IN
        nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN expression_NN observed_VBD in_IN human_JJ breast_NN
        tumors_NNS is_VBZ likely_JJ a_DT post-transcriptional_JJ event_NN ._.
        Results_NNS from_IN Western_JJ blot_NN analyses_NNS with_IN polyclonal_NN
        antibodies_NNS NMT-_NNP 4_CD and_CC NMT-_NNP 5_CD showed_VBD that_DT nmt_NN 55_CD /_NN p_NN 54_CD
        nrbexpression_NN was_VBD absent_JJ ,_, or_CC greatly_RB reduced_VBN ,_, in_IN most_JJS of_IN
        ER-_NNP tumors_NNS ._. This_DT confirmed_VBD the_DT previous_JJ observations_NNS
        obtained_VBN with_IN monoclonal_NN antibody_NN NMT-_NNP 1_CD [_NN 13_CD ]_NN ._. Data_NNP also_RB
        showed_VBD that_IN a_DT subset_NN of_IN ER_NNP +_NN tumors_NNS expressed_VBD nmt_NN 55_CD /_NN p_NN 54_CD
        nrbprotein_NN detectable_JJ with_IN polyclonal_NN antibody_NN NMT-_NNP 5_CD and_CC
        monoclonal_NN antibody_NN NMT-_NNP 1_CD but_CC not_RB polyclonal_NN antibody_NN
        NMT-_NNP 4_CD ._. These_DT results_NNS suggested_VBD the_DT presence_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD
        nrbvariants_NNS in_IN a_DT subset_NN of_IN ER_NNP +_NN human_JJ breast_NN tumors_NNS ._. The_DT
        inability_NN of_IN polyclonal_NN antibody_NN NMT-_NNP 4_CD to_TO detect_VB nmt_NN 55_CD /_NN p_NN 54_CD
        nrbin_NN some_DT ER_NNP +_NN tumors_NNS may_MD be_VB attributed_VBN to_TO proteolysis_NNS
        during_IN nuclear_JJ extraction_NN and_CC analyses_NNS or_CC biochemical_JJ
        modification_NN of_IN functionally_RB distinct_JJ isoform_NN ._. While_IN the_DT
        altered_VBN molecular_JJ weight_NN of_IN the_DT protein_NN sample_NN shown_VBN in_IN
        Figure_NN 6_CD ,_, lane_NN 9_CD may_MD be_VB attributed_VBN to_TO proteolysis_NNS ,_, most_JJS of_IN
        the_DT protein_NN samples_NNS in_IN Figure_NN 6_CD displayed_VBD a_DT similar_JJ
        estimated_VBN molecular_JJ weight_NN of_IN 55_CD kDa_NN ._. Thus_RB ,_, the_DT lack_NN of_IN
        nmt_NN 55_CD /_NN p_NN 54_CD nrb_NN protein_NN detection_NN in_IN this_DT study_NN is_VBZ most_RBS likely_JJ
        not_RB due_JJ to_TO proteolysis_NNS ._. We_PRP also_RB wanted_VBD to_TO determine_VB if_IN
        nmt_NN 55_CD /_NN p_NN 54_CD nrbvariants_NNS detected_VBD with_IN polyclonal_NN antibody_NN
        NMT-_NNP 5_CD and_CC monoclonal_NN antibody_NN NMT-_NNP 1_CD but_CC not_RB polyclonal_NN
        antibody_NN NMT-_NNP 4_CD using_VBG nuclear_JJ extracts_NNS and_CC Western_JJ blot_NN
        analyses_NNS were_VBD also_RB detectable_JJ in_IN intact_JJ cells_NNS ._. To_TO test_VB this_DT
        premise_NN ,_, we_PRP utilized_JJ immunohistochemistry_NN to_TO detect_VB
        nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN in_IN human_JJ breast_NN tumor_NN tissue_NN sections_NNS ._.
        The_DT data_NNS from_IN immunohistochemistry_NN confirmed_VBD the_DT results_NNS
        obtained_VBN by_IN Western_JJ blot_NN analyses_NNS ,_, which_WDT suggested_VBD that_DT
        nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN was_VBD expressed_VBN in_IN various_JJ isoforms_NNS in_IN a_DT
        subset_NN of_IN ER_NNP +_NN human_JJ breast_NN tumors_NNS ._. These_DT potential_JJ isoforms_NNS
        may_MD have_VB altered_VBN biological_JJ function_NN due_JJ to_TO the_DT loss_NN of_IN
        domain_NN specific_JJ interactions_NNS ._. We_PRP have_VBP attempted_VBN to_TO
        ascertain_VB the_DT presence_NN and_CC nature_NN of_IN these_DT isoforms_NNS by_IN
        utilizing_VBG mixing_VBG experiments_NNS ;_: however_RB ,_, these_DT experiments_NNS
        have_VBP proved_VBN inconclusive_JJ ._. The_DT expression_NN and_CC role_NN of_IN this_DT
        isoform_NN in_IN human_JJ breast_NN cancer_NN remains_VBZ to_TO be_VB
        determined_VBN ._.
        A_DT plausible_JJ explanation_NN for_IN the_DT lack_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD
        nrbprotein_NN detection_NN with_IN polyclonal_NN antibody_NN NMT-_NNP 4_CD is_VBZ a_DT
        point_NN mutation_NN in_IN the_DT epitope_NN for_IN polyclonal_NN antibody_NN
        NMT-_NNP 4_CD ,_, a_DT post-translational_JJ modification_NN ,_, such_JJ as_IN
        phosphorylation_NN ,_, in_IN or_CC near_IN this_DT epitope_NN or_CC an_DT alternative_JJ
        splice_NN variant_NN affecting_VBG this_DT epitope_NN ._. Another_DT possibility_NN
        is_VBZ the_DT methylation_NN of_IN arginine_NN residues_NNS ;_: although_IN this_DT
        would_MD not_RB alter_VB the_DT overall_JJ charge_NN of_IN the_DT protein_NN ,_, it_PRP could_MD
        sterically_RB hinder_VB the_DT protein_NN /_NN antibody_NN interaction_NN ._. The_DT
        methylation_NN of_IN arginine_NN residues_NNS has_VBZ been_VBN shown_VBN to_TO take_VB
        place_NN in_IN other_JJ pre-m_JJ RNA_NNP splicing_VBG proteins_NNS though_IN the_DT role_NN
        of_IN this_DT modification_NN is_VBZ unknown_JJ [_NN 38_CD ]_NN ._. One_CD approach_NN to_TO
        determine_VB the_DT presence_NN of_IN a_DT point_NN mutation_NN or_CC a_DT splice_NN
        variant_NN is_VBZ to_TO perform_VB PCR_NNP coupled_VBN with_IN sequencing_VBG
        techniques_NNS ._. Another_DT approach_NN to_TO resolve_VB this_DT issue_NN is_VBZ to_TO
        analyze_VB this_DT protein_NN isoform_NN by_IN Mass_NNP Spectroscopy_NNP ._. These_DT
        studies_NNS are_VBP currently_RB under_IN investigation_NN ._.
        In_IN this_DT report_NN ,_, we_PRP show_VBP that_DT nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN is_VBZ
        expressed_VBN in_IN a_DT variant_NN isoform_NN in_IN a_DT subset_NN of_IN ER_NNP +_NN tumors_NNS ._.
        These_DT data_NNS ,_, along_IN with_IN our_PRP$ previous_JJ observations_NNS ,_, suggest_VBP
        that_IN the_DT association_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrband_NN hERα_NN expression_NN
        represents_VBZ three_CD separate_JJ human_JJ breast_NN tumor_NN phenotypes_NNS ._.
        The_DT first_JJ phenotype_NN represents_VBZ tumors_NNS that_WDT express_VBP wild_JJ
        type_NN nmt_NN 55_CD /_NN p_NN 54_CD nrband_NN are_VBP ER_NNP +_NN ._. These_DT tumors_NNS may_MD be_VB
        classified_VBN as_IN low_JJ grade_NN or_CC early_JJ stage_NN tumors_NNS and_CC respond_VB
        well_RB to_TO endocrine_NN manipulations_NNS ._. The_DT second_JJ phenotype_NN is_VBZ
        identified_VBN as_IN ER_NNP +_NN using_VBG Western_JJ blot_NN or_CC immunohistochemical_JJ
        analyses_NNS and_CC would_MD express_VB the_DT amino_JJ terminal_NN
        altered_VBD /_NN modified_VBN nmt_NN 55_CD /_NN p_NN 54_CD nrbisoform_NN ._. This_DT may_MD represent_VB
        mid-grade_JJ and_CC mid-stage_JJ tumors_NNS which_WDT are_VBP very_RB
        heterogeneous_JJ ._. It_PRP would_MD be_VB of_IN interest_NN to_TO determine_VB if_IN
        these_DT tumors_NNS express_VBP nonfunctional_NN hERα_NN and_CC ,_, as_IN a_DT result_NN ,_,
        do_VBP not_RB respond_VB to_TO hormonal_NN therapy_NN ._. Finally_RB ,_, the_DT third_JJ
        phenotype_NN represents_VBZ tumors_NNS that_WDT do_VBP not_RB express_VB hERα_NN and_CC
        nmt_NN 55_CD /_NN p_NN 54_CD nrb_NN ._. These_DT tumors_NNS would_MD most_RBS likely_JJ be_VB highly_RB
        proliferative_JJ ,_, classified_VBN as_IN high_JJ grade_NN and_CC late_JJ stage_NN ,_,
        hormone_NN insensitive_JJ and_CC potentially_RB metastatic_JJ ._. While_IN the_DT
        focus_NN of_IN this_DT study_NN has_VBZ been_VBN the_DT biochemical_JJ relationship_NN
        between_IN nmt_NN 55_CD /_NN p_NN 54_CD nrband_NN tumor_NN hormonal_NN status_NN ,_, a_DT more_RBR
        expansive_JJ study_NN correlating_VBG nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN expression_NN
        with_IN various_JJ breast_NN tumor_NN clinicopathological_JJ
        characteristics_NNS may_MD provide_VB additional_JJ key_JJ information_NN ._.
        These_DT studies_NNS are_VBP under_IN investigation_NN ._.
        Our_PRP$ data_NNS suggests_VBZ that_DT nmt_NN 55_CD /_NN p_NN 54_CD nrbmay_NN be_VB critical_JJ to_TO
        cell_NN growth_NN and_CC function_NN ,_, such_JJ that_IN ,_, decreased_VBD nmt_NN 55_CD /_NN p_NN 54_CD
        nrbexpression_NN in_IN ER-_NNP human_JJ breast_NN tumors_NNS or_CC the_DT expression_NN
        of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbvariants_NNS in_IN ER_NNP +_NN tumors_NNS may_MD indicate_VB loss_NN of_IN
        normal_JJ growth_NN ,_, nmt_NN 55_CD /_NN p_NN 54_CD nrbhas_NNS been_VBN shown_VBN in_IN several_JJ
        studies_NNS to_TO bind_NN RNA_NNP and_CC interact_NN with_IN PSF_NNP and_CC Topoisomerase_NNP
        I_PRP [_NN 14_CD 16_CD 17_CD 18_CD 19_CD 20_CD 39_CD ]_NN ._. Those_DT results_NNS along_IN with_IN our_PRP$
        observations_NNS that_WDT nmt_NN 55_CD /_NN p_NN 54_CD nrbassociates_NNS with_IN several_JJ
        splicing_VBG factors_NNS essential_JJ for_IN spliceosome_NN formation_NN
        (_( unpublished_JJ )_) and_CC relates_VBZ to_TO tumor_NN hormonal_NN status_NN [_NN 13_CD ]_NN
        suggest_VBP that_DT nmt_NN 55_CD /_NN p_NN 54_CD nrbmay_NN be_VB involved_VBN in_IN pre-m_JJ RNA_NNP
        processing_NN ._. Thus_RB ,_, loss_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN or_CC the_DT
        expression_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbprotein_NN variants_NNS in_IN tumor_NN cells_NNS
        may_MD result_VB in_IN the_DT loss_NN of_IN hERα_NN expression_NN ,_, the_DT expression_NN
        of_IN nonfunctional_NN hERα_NN or_CC the_DT altered_VBN expression_NN other_JJ
        critical_JJ cell_NN growth_NN factors_NNS due_JJ to_TO lack_NN of_IN proper_JJ pre-m_JJ RNA_NNP
        splicing_VBG ._.
        Specifically_RB ,_, the_DT role_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbas_NNS a_DT splicing_VBG
        factor_NN may_MD affect_VB hERα_NN structure_NN and_CC function_NN ._. The_DT
        progression_NN of_IN breast_NN cancer_NN may_MD be_VB associated_VBN with_IN changes_NNS
        in_IN RNA_NNP processing_NN and_CC the_DT production_NN of_IN aberrantly_RB spliced_JJ
        mRNAs_NNS ,_, which_WDT may_MD result_VB in_IN non-functional_JJ gene_NN products_NNS or_CC
        the_DT loss_NN of_IN specific_JJ gene_NN expression_NN ._. It_PRP has_VBZ been_VBN proposed_VBN
        that_DT loss_NN of_IN hERα_NN expression_NN in_IN breast_NN tumors_NNS is_VBZ the_DT result_NN
        of_IN aberrant_NN RNA_NNP processing_NN [_NN 40_CD 41_CD 42_CD 43_CD ]_NN ._. These_DT
        aberrantly_RB spliced_JJ mRNAs_NNS ,_, if_IN translated_VBN ,_, could_MD lead_VB to_TO
        truncated_JJ receptors_NNS with_IN hormone_NN binding_JJ but_CC not_RB DNA_NNP
        binding_JJ function_NN [_NN 44_CD ]_NN ._. Further_RB ,_, there_EX is_VBZ evidence_NN for_IN
        the_DT role_NN of_IN RNA_NNP processing_NN in_IN oncogenesis_NNS [_NN 45_CD 46_CD ]_NN ._. Many_JJ
        studies_NNS ,_, including_VBG those_DT on_IN human_JJ hnRNP_NN A_DT 2_CD /_NN B_NNP 1_CD and_CC the_DT CD_NNP 44_CD
        gene_NN ,_, suggest_VBP that_IN high_JJ fidelity_NN pre-m_JJ RNA_NNP splicing_VBG is_VBZ
        critical_JJ to_TO normal_JJ cellular_JJ function_NN and_CC may_MD play_VB a_DT key_JJ
        role_NN in_IN oncogenesis_NNS and_CC breast_NN cancer_NN progression_NN [_NN 47_CD 48_CD ]_NN
        ._. The_DT strong_JJ association_NN between_IN nmt_NN 55_CD /_NN p_NN 54_CD nrband_NN hERα_NN
        expression_NN indicates_VBZ that_DT nmt_NN 55_CD /_NN p_NN 54_CD nrbmay_NN be_VBP an_DT important_JJ
        marker_NN for_IN breast_NN cancer_NN progression_NN ._. The_DT decreased_VBD or_CC
        altered_VBN expression_NN of_IN nmt_NN 55_CD /_NN p_NN 54_CD nrbmay_NN be_VB related_VBN to_TO tumor_NN
        differentiation_NN ,_, unregulated_JJ tumor_NN cell_NN growth_NN and_CC
        metastases_NNS and_CC may_MD explain_VB tumor_NN heterogeneity_NN ,_, especially_RB
        with_IN respect_NN to_TO hormonal_NN interventions_NNS in_IN the_DT course_NN of_IN
        treatment_NN ._. Although_IN an_DT RNA_NNP splicing_VBG protein_NN ,_, hnRNP_NN A_DT 2_CD /_NN B_NNP 1_CD ,_,
        has_VBZ been_VBN used_VBN as_IN a_DT tumor_NN marker_NN in_IN lung_NN cancer_NN progression_NN
        [_NN 47_CD ]_NN ,_, this_DT is_VBZ the_DT first_JJ time_NN that_IN a_DT protein_NN involved_VBN in_IN
        pre-m_JJ RNA_NNP splicing_VBG has_VBZ been_VBN implicated_VBN in_IN breast_NN cancer_NN
        progression_NN and_CC may_MD represent_VB an_DT important_JJ breast_NN tumor_NN
        marker_NN ._. Further_RB studies_VBZ are_VBP necessary_JJ to_TO determine_VB a_DT
        functional_JJ link_NN between_IN this_DT RNA_NNP binding_JJ protein_NN and_CC hERα_NN
        in_IN human_JJ breast_NN cancer_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
